Entrada Therapeutics, Inc. (TRDA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$7.13-0.56%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Broken: Primary pillar broken — Revenue growth to reverse decline and approach $29.8M in 2027: FY26 rev $10.6M vs $15M trip.
Entrada advances RNA therapies for rare diseases. Analysts expect revenue to fall about 60% next year but then nearly double to $29.8M in 2027. The company has reported three recent earnings beats and formed a strategic partnership in 2026.
Revenue is expected to decline 60% next year to about $15M. The company remains unprofitable with EPS around -$3.79 in 2026. Recent sharp stock selloff and negative free cash flow raise risks for recovery.
The market prices in a 60% revenue decline next year and continued losses. Our fair value near $2.54 reflects this weak outlook. We differ by seeing optionality if clinical progress improves but risk remains high.
Breaks if: Failure to advance clinical trials or loss of partnerships
Breaks if: EPS loss worsens beyond -$3.79 in FY26
revenue falls below $15 million in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently loss-making but is focused on advancing its clinical programs, particularly in Duchenne muscular dystrophy. The thesis is in a watch state due to mixed recent performance and elevated risks.
The market appears to have priced in a significant expectations gap, indicating that TRDA's current valuation reflects a premium compared to peers. There is a sense of unjustified optimism, as the company has not demonstrated consistent financial performance relative to its industry cohort.
Management has shown stability in priorities, with a focus on reporting clinical data by year-end 2026 and maintaining a cash runway into 2027. However, the recent decline in company momentum and mixed financial results suggest that fundamentals may face challenges in the near term.
The most important moves since the prior daily snapshot.
Mixed, the news cuts both ways. The latest earnings beat supports the read on TRDA. However, Mpm Bioventures selling a significant amount of stock threatens the company's cash runway. This sale may impact perceptions about TRDA's financial stability.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
The long-term thesis hinges on the company's ability to deliver on clinical milestones and maintain its cash runway. Additionally, external factors such as sector performance and macroeconomic conditions, including job reports, could significantly impact TRDA's trajectory.
Overall, TRDA's outlook is uncertain, influenced by both internal execution and external market conditions. Not investment advice.